Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit
Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit
First in Sphere Fluidics’ new range of 3D cell culture kits in partnership with ClexBio
Cambridge, UK and Oslo, Norway, 7 June 2021: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit. The kit combines ClexBio’s novel CYTRIX Hydrogel with Sphere Fluidics’ specially designed Pico-Gen™ double aqueous biochip to allow the plug-and-play generation of defined, reproducible and tailorable hydrogel microstructures for 3D cell culture, organoids, single-cell analysis, and many other applications. This allows researchers to study valuable cells over many weeks rather than days in defined microenvironments that mimic the natural extracellular matrix.
The CYTRIX Hydrogel overcomes the challenges of existing microfluidic hydrogel formation techniques, such as clogging, finicky temperature control or time-critical mixing procedures. It offers cytocompatibility and microfluidic-optimized gelation kinetics, providing researchers with a cell-friendly solution to reduce the effect of harmful temperatures, pH changes and use of UV-light required for existing hydrogel formation techniques. Paired with the Sphere Fluidics Pico-Gen double aqueous biochip and microfluidics, the CYTRIX Hydrogel enables efficient encapsulation of mammalian cells, bacteria, and other microorganisms in a homogeneous and defined extracellular matrix that supports cell viability.
Dr. Xin Li, Associate Director of Science at Sphere Fluidics said: “The CYTRIX Microfluidic Hydrogel Kit mimics the 3D microenvironment and helps researchers explore the potential of hydrogel-based microfluidics in tissue engineering, drug discovery and regenerative medicine over many weeks.”
Dr. Armend Håti, CEO and Co-Founder of ClexBio said: “This exciting collaboration with Sphere Fluidics has enabled us to deliver one of the first commercial solutions that allows simple and cell-friendly formation of cell-laden microgels, lengthening the time that researchers can study the contents of microspheres.”
For further information about the CYTRIX Microfluidic Hydrogel Kit, please visit: https://spherefluidics.com/microfluidic-hydrogel/
About Sphere Fluidics www.spherefluidics.com
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable leading edge research and accelerate biotherapeutic discovery and development. The Company’s picodroplet incubation technology enables ultra-sensitive, rapid miniaturized assays of target protein secreted from tens of millions of individual cells.
Sphere Fluidics’ Cyto-Mine® System integrates isolation, selective screening, sorting, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Its Picodroplet Single Cell Analysis and Isolation System offers state-of-the-art microfluidics technology inside an easy-to-use, semi-automated system, designed with the flexibility to easily integrate into research processes.
Sphere Fluidics is located in Babraham Research Campus and Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.
Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.
About ClexBio www.clexbio.com
ClexBio is a Norway-based biotech company creating breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with the proprietary hydrogel technology CLEX. The CLEX technology was developed through years of research in leading microfluidic labs at Harvard University, NTNU, and EPFL. The technology allows the encapsulation of sensitive biological materials such as living cells using state-of-the-art microfluidic technology. Compared to existing solutions, this facilitates:
- The production of significantly smaller cell-laden structures (up to 100x increased resolution)
- Unprecedented biocompatibility (up to 10x higher cell viability)
- Seamless integration with existing hardware (from microfluidics to 3D bioprinting and beyond)
For inquiries please contact contact@clexbio.com. Find out more at www.clexbio.com and follow ClexBio on LinkedIn. The private company ClexBio is registered in Norway under the name Nordovo Biosciences AS.
